56 related articles for article (PubMed ID: 1403231)
1. The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters.
Lees KR
J Hypertens Suppl; 1992 Jul; 10(5):S3-11. PubMed ID: 1403231
[TBL] [Abstract][Full Text] [Related]
2. Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors.
Salvetti A; Di Venanzio L; Arrighi P; Arzilli F
J Hypertens Suppl; 1994 Nov; 12(8):S91-4; discussion S94-5. PubMed ID: 7707164
[TBL] [Abstract][Full Text] [Related]
3. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?
Raasch W; Bartels T; Schwartz C; Häuser W; Rütten H; Dominiak P
J Hypertens; 2002 Dec; 20(12):2495-504. PubMed ID: 12473875
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Wallis EJ; Ramsay LE; Hettiarachchi J
Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
Song JC; White CM
Clin Pharmacokinet; 2002; 41(3):207-24. PubMed ID: 11929321
[TBL] [Abstract][Full Text] [Related]
6. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?
van den Meiracker AH; Man in 't Veld AJ; Admiraal PJ; Ritsema van Eck HJ; Boomsma F; Derkx FH; Schalekamp MA
J Hypertens; 1992 Aug; 10(8):803-12. PubMed ID: 1325513
[TBL] [Abstract][Full Text] [Related]
7. Experience with perindopril in normal volunteers.
Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():35-41. PubMed ID: 2549899
[TBL] [Abstract][Full Text] [Related]
8. Experience with perindopril in normal volunteers.
Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
Clin Exp Hypertens A; 1989; 11 Suppl 2():507-19. PubMed ID: 2605800
[TBL] [Abstract][Full Text] [Related]
9. Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin.
Montenegro MF; Pessa LR; Tanus-Santos JE
Eur J Pharmacol; 2009 Apr; 607(1-3):173-7. PubMed ID: 19233159
[TBL] [Abstract][Full Text] [Related]
10. Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report.
Karlberg BE; Fyhrquist F; Grönhagen-Riska C; Tikkanen I; Ohman KP
Scand J Urol Nephrol Suppl; 1984; 79():103-6. PubMed ID: 6089307
[TBL] [Abstract][Full Text] [Related]
11. Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males.
Morgan TO; Morgan O; Anderson A
Clin Exp Pharmacol Physiol; 1995 Oct; 22(10):778-80. PubMed ID: 8575118
[TBL] [Abstract][Full Text] [Related]
12. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting ex vivo inhibition by perindopril of rat vascular response to angiotensin I.
Ishigai Y; Fukuzawa A; Chiba K; Irie K; Shibano T
Methods Find Exp Clin Pharmacol; 1994 Nov; 16(9):633-8. PubMed ID: 7746024
[TBL] [Abstract][Full Text] [Related]
14. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
[TBL] [Abstract][Full Text] [Related]
15. Trandolapril dose-response in spontaneously hypertensive rats: effects on ACE activity, blood pressure, and cardiac hypertrophy.
Jouquey S; Stepniewski JP; Hamon G
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S16-8. PubMed ID: 7527096
[TBL] [Abstract][Full Text] [Related]
16. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
Johnston CI; Jackson B; McGrath B; Matthews G; Arnolda L
J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism.
Jiménez-Ferrer E; Badillo FH; González-Cortazar M; Tortoriello J; Herrera-Ruiz M
J Ethnopharmacol; 2010 Jul; 130(2):340-6. PubMed ID: 20488233
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
20. Correlation between ACE activity and mean blood pressure in Iranian normotensive subjects after oral administration of a single dose of enalapril.
Ziai SA; Seyedhosseini D; Taiebi L; Salekmoghadam E; Mahmoudian M
Acta Physiol Hung; 2000; 87(2):153-9. PubMed ID: 11205963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
